ORCID verified
25 Jun 2026Open access
Comparative analysis of empirical evapotranspiration models across Northern Ethiopia’s Climatic ZonesPublisher siteScientific Reports, Plant Water Relations and Carbon Dynamics
Active, last published 2026
In menopause: health impacts and treatments
Hana
Mekonnen
Pioneer
Scholar“Research focused on Menopause: Health Impacts and Treatments and adjacent fields.”
4
H-index
274
Citations
This profile has been officially claimed and verified.
Honours
Pioneer
#2708
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
ana Mekonnen is a researcher working on Menopause: Health Impacts and Treatments. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Hana's work has been cited 274 times across 5 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Menopause: Health Impacts and Treatments×4Sexual function and dysfunction studies×2Nausea and vomiting management×2
04 · Where I am
Affiliations
Affiliation on published researchBahir Dar University, EthiopiaDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
9 works1 May 2026Open access
Performance assessment of empirical reference evapotranspiration estimation models on a seasonal basis in Northern EthiopiaPublisher siteHydrology research, Plant Water Relations and Carbon Dynamics
30 Aug 2023Open access1cites
A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumorsPublisher sitePLoS ONE, Renal cell carcinoma treatment
1 Jun 2023
439 Patients with mild to moderate atopic dermatitis: a first-in-human, open-label, dose-escalating, nonrandomized clinical trial with AMTX-100Publisher siteBritish Journal of Dermatology, Dermatology and Skin Diseases
20 Apr 201850cites
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infectionPublisher siteHIV Clinical Trials, HIV Research and Treatment
19 Aug 2014Open access49cites
Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopausePublisher siteMenopause The Journal of The North American Menopause Society, Menopause: Health Impacts and Treatments
28 Apr 2014
Safety Profile of Paroxetine 7.5 mg in Women With Moderate-to-Severe Vasomotor SymptomsPublisher siteObstetrics and Gynecology, Menopause: Health Impacts and Treatments
19 Feb 2014Open access29cites
Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopausePublisher siteMenopause The Journal of The North American Menopause Society, Sexual function and dysfunction studies
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Interested in this research?
MARATTO™ facilitates research-to-market partnerships between African universities and industry. Book a discovery call to explore collaboration with Hana Mekonnen.